• Geneticin, G-418 Sulfate: Precision Selection and Mechanisti

  2026-05-11

  Explore the advanced use of Geneticin, G-418 Sulfate in genetic engineering and antiviral research, with a focus on its mechanistic action and protocol optimization. This article provides unique, evidence-driven guidance beyond standard workflows.

• Sorafenib (BAY-43-9006): Unlocking Multikinase Inhibition in

  2026-05-11

  Explore the advanced use of Sorafenib (BAY-43-9006) as a precise, multi-targeted tool for dissecting tumor proliferation and angiogenesis in liver cancer models. This cornerstone article uniquely bridges mechanistic insight with assay optimization, offering practical guidance for cancer biology research.

• AZD2461: Advanced Assay Strategies for PARP Inhibitor Resear

  2026-05-10

  Explore how the novel PARP inhibitor AZD2461 empowers breast cancer research through robust, evidence-driven assay design. Uncover practical, scientifically grounded methods to optimize DNA repair pathway studies and overcome drug resistance.

• Abiraterone Acetate (SKU A8202): Optimizing Prostate Cancer

  2026-05-09

  This article addresses real-world lab challenges in prostate cancer research, focusing on the role of Abiraterone acetate (SKU A8202) as a potent CYP17 inhibitor. By exploring experimental design, protocol optimization, and data interpretation, it demonstrates how SKU A8202 supports reproducible, high-sensitivity androgen pathway assays. Researchers will find scenario-driven guidance and evidence-based recommendations to maximize the reliability and translational value of their workflows.

• Nicotinamide Riboside Chloride (NIAGEN): NAD+ Metabolism in

  2026-05-09

  Nicotinamide Riboside Chloride (NIAGEN) is a validated NAD+ precursor that enhances cellular energy metabolism and sirtuin activity. Its high purity and solubility profile support reproducible metabolic dysfunction and neurodegenerative disease modeling in preclinical workflows.

• TECPR1-Mediated Lysosomal Repair Under Energy Stress: Mechan

  2026-05-08

  This study identifies TECPR1 as a crucial mediator of lysosomal membrane repair during energy crisis, uncovering its interaction with PI4P and KIF1A to drive membrane tubulation that preserves lysosomal integrity. The work advances our understanding of lysosomal quality control and has important implications for metabolic disease and experimental workflows reliant on intact protein complexes.

• BKT140 (BL-8040): Precision CXCR4 Antagonist for Oncology Wo

  2026-05-07

  BKT140 (BL-8040) empowers translational cancer research with robust CXCR4-mediated chemotaxis inhibition, apoptosis induction, and stem cell mobilization. This guide details optimized experimental workflows and troubleshooting strategies that maximize BKT140's impact in advanced tumor models and hematopoietic assays.

• Strategic Use of Y-27632: Advancing Translational Cell Biolo

  2026-05-07

  This thought-leadership article explores how Y-27632 dihydrochloride, a potent ROCK1/2 inhibitor from APExBIO, empowers translational researchers to engineer the cell microenvironment, enhance stem cell viability, and suppress tumor invasion. By bridging mechanistic insight with experimental best practices and strategic foresight, it addresses the evolving needs of modern biologists, referencing the latest microfabrication workflows and real-world protocol optimizations.

• Urolithin A: Mechanisms and Benchmarks for Mitochondrial Res

  2026-05-06

  Urolithin A, a gut microbiota-derived metabolite known as 3,8-dihydroxy-6H-benzo[c]chromen-6-one, supports mitochondrial quality control by activating mitophagy and enhancing mitochondrial biogenesis. This dossier synthesizes current evidence on its mechanism of action, performance benchmarks, and applications in mitochondrial biogenesis research and anti-inflammatory interventions.

• PtrbZIP12 Directly Regulates Drought Response via Phosphoryl

  2026-05-06

  This study elucidates how the bZIP transcription factor PtrbZIP12 enhances drought resistance in Populus trichocarpa by directly activating PtrDHN and PtrPOD genes. The findings establish phosphorylation as a critical regulatory mechanism, offering new targets for plant stress resilience engineering.

• 3D Organoid–Fibroblast Co-culture Models PDAC Chemoresistanc

  2026-05-05

  Schuth et al. present a patient-specific 3D organoid–fibroblast co-culture system that reveals how cancer-associated fibroblasts (CAFs) drive chemoresistance in pancreatic ductal adenocarcinoma (PDAC). This model advances understanding of tumor-stroma interactions and provides a robust platform for evaluating drug responses and dissecting molecular mechanisms of resistance.

• Tubastatin A (A4101): Reliable HDAC6 Inhibition in Cell-Base

  2026-05-05

  Discover how Tubastatin A (SKU A4101) addresses core challenges in cell viability, proliferation, and cytotoxicity assays by delivering highly selective HDAC6 inhibition. This scenario-driven guide provides practical insights, protocol parameters, and data-backed recommendations for researchers seeking reproducible outcomes in cancer biology, inflammation, and myocardial injury models.

• ICG001 for Translational Control of Wnt/β-Catenin in Fibrosi

  2026-05-04

  This thought-leadership article explores how ICG001, a selective Wnt/β-catenin pathway inhibitor, empowers translational researchers to dissect and therapeutically target the CBP/β-catenin signaling axis in fibrosis and cancer. Integrating mechanistic insights from recent studies on EMT-driven liver fibrosis, the article provides strategic guidance on experimental design, protocol optimization, and clinical translation. By bridging foundational science and actionable workflows, it positions ICG001 as a pivotal tool for advancing fibrosis research beyond conventional paradigms.

• Oteseconazole (VT-1161): Mechanistic Insights and Clinical F

  2026-05-04

  Discover how Oteseconazole (VT-1161) advances antifungal therapy for Candida infections through its selective CYP51 inhibition. This article provides a mechanistic deep dive and strategic guidance for precision research and clinical application.

• Human iPSC-Derived Intestinal Organoids for PK Studies

  2026-05-03

  This study introduces a rapid and reliable protocol for generating human intestinal organoids from induced pluripotent stem cells (hiPSCs), overcoming prior limitations of time-consuming, multi-step differentiation. The platform provides a physiologically relevant in vitro system for pharmacokinetic assessment of orally administered drugs, offering improved modeling over animal or cancer cell line alternatives.

442 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page